Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC Vaccination in Lynch Syndrome and MSI CRC
NCT01885702Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2010
- Primary completion
- Apr 2016
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of frameshift-derived neoantigen-loaded dendritic cell vaccine in colorectal cancer (CRC) and Lynch syndrome (LS), sponsored by Radboud University Medical Center. Started Oct 2010; status: active, not recruiting.
02
Drugs
frameshift-derived neoantigen-loaded dendritic cell vaccine
03
Conditions
colorectal cancer (CRC)Lynch syndrome (LS)
Beyond the preview
Go deeper on NCT01885702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01885702.